

TRIAL EVALUATING CARDIOVASCULAR
TECOS
OUTCOMES WITH SITAGLIPTIN

Trial Evaluating Cardiovascular Outcomes with
Sitagliptin in Subjects with Type 2 Diabetes

Have you been diagnosed with Type 2 Diabetes Mellitus and Cardiovascular Disease?

You may be eligible to participate in a research study looking at
cardiovascular effects of sitagliptin, a diabetes medication.

What is the reason for TECOS?

We know that control of blood sugar in diabetes will reduce the risk of damage in the eyes, kidneys, and nerves. There are now many types of medications available to lower blood sugars and help prevent these complications; however, it is possible that these medications may affect the cardiovascular system in different ways.

In TECOS, researchers will be comparing 2 groups to see what differences there might be:

Comparing

Group 1

The likelihood of having a cardiovascular event while receiving typical treatment for type 2 diabetes mellitus including sitagliptin.

Group 2

The likelihood of having a cardiovascular event while on typical treatment for type 2 diabetes mellitus not including sitagliptin.



Who is able to take part?

You may be able to take part if you:

1. Have a diagnosis of type 2 diabetes.
2. Are at least 50 years old.
3. Are on 1 or 2 oral medications to lower your blood sugar (metformin, pioglitazone, or a medicine like glipizide/glimepiride) that have remained unchanged for the last 3 months.
4. Are not taking insulin injections

To Learn More, Contact:

Clinic Name: Prohealth Clinical Research
Study coordinator/doctor:
Dr. E. Ur/Juliet Algoso
Phone Number: 604-263-3661